Accreditation

0.75 AMA PRA Category 1 Credit(s)™.
Read the full Accreditation Statement

Target Audience

This activity will be directed to rheumatologists, gastroenterologists, dermatologists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapeutics in autoimmune and inflammatory disorders.

Description

This activity was presented at the Cleveland Clinic Richard J. Fasenmyer Center of Clinical Immunology Biologic Therapies for Autoimmune and Inflammatory Disease States Summit. The summit reviewed advances in biologic therapies for autoimmune diseases.

Objectives

At the conclusion of this activity, the participant will be able to:

1. Recognize the role of whole genome screens in defining disease causation.
2. Identify key players in the innate immune response to acute injury and to chronic debris deposition.
3. Explain the background in genetics and immunity to demonstrate how one player in innate immunity, the complement system, participates in hemolytic uremic syndrome and age-related macular degeneration.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology

Author

John Atkinson, MD

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest: